Silk Road Medical

丝绸之路医疗

(Nasdaq:SILK)

（纳斯达克：丝绸）

+

+

today filed with the SEC to confirm the expiration of an antitrust waiting period for its merger with Boston Scientific

今天向美国证券交易委员会提交了文件，确认其与波士顿科学公司合并的反垄断等待期已经结束

(NYSE: BSX)

（纽约证券交易所：BSX）

+

+

.

.

In June, Boston Scientific announced that it agreed to acquire Silk Road Medical in a deal worth approximately $1.16 billion. Sunnyvale, California-based Silk Road Medical develops products designed to prevent stroke in patients with carotid artery disease. The technology is used in a minimally invasive procedure called transcarotid artery revascularization (TCAR)..

6月，波士顿科学宣布同意以约11.6亿美元的价格收购丝绸之路医疗。总部位于加利福尼亚州桑尼维尔的丝绸之路医疗公司开发了旨在预防颈动脉疾病患者中风的产品。该技术用于一种称为经颈动脉血运重建（TCAR）的微创手术。。

However, last month, Boston Scientific voluntarily withdrew its premerger notification and report form. This aimed to give the U.S. Federal Trade Commission (FTC) more time to review the proposed acquisition. Meanwhile, Boston Scientific also faced FTC scrutiny over its proposed acquisition of Axonics, which remains ongoing..

然而，上个月，波士顿科学公司（Boston Scientific）自愿撤回了其premerger通知和报告表。这旨在给美国联邦贸易委员会（FTC）更多的时间来审查拟议的收购。与此同时，波士顿科学公司（Boston Scientific）也面临联邦贸易委员会（FTC）对其拟议收购Axonics的审查，该收购仍在进行中。。

Silk Road Medical said today that its stockholders voted to adopt the merger agreement at a special meeting on Sept. 5. Completion is conditioned upon, among other things, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) of 1976..

丝绸之路医疗今天表示，其股东在9月5日的特别会议上投票通过了合并协议。根据1976年《哈特·斯科特·罗迪诺反托拉斯改进法案》（HSR Act），完成交易的条件包括适用等待期的到期或终止。。

On Sept. 12, the applicable waiting period under the HSR Act expired at 11:59 p.m. ET, according to the SEC Form 8-K.

根据SEC表格8-K，9月12日，《高铁法案》规定的适用等待期于美国东部时间下午11:59到期。

Subject to the remaining merger conditions, Boston Scientific and Silk Road expect to complete the transaction in the coming days.

根据剩余的合并条件，波士顿科学和丝绸之路预计将在未来几天完成交易。